Indication: Tukysa, a kinase inhibitor

Tuksya is a kinase inhibitor recommended in combination with Trastuzumab and Capecitabine for treating adult patients with advanced unresectable or metastatic HER2-positive breast cancer, including patients with brain metastases who received one or more prior anti-HER2-based regimens in the metastatic setting and in combination with Trastuzumab for the treatment of adult patients with RAS wild-type HER2-positive […]

Overview Breast cancer, including patients with brain metastases.

As per the the Duke Center for Brain and Spine Metastases studies, Breast cancer is the most common cancer in women, with 276, 480 new cases predicted for the year 2020 in the United States alone.1 It is also the second most common cause of brain metastases (BrM), with different reports indicating variable 10% to 30% […]